諾輝健康發佈常衞清香港上市百日戰報:銷售6000人/份,到檢逾2000人/份
格隆匯9月27日丨諾輝健康今日發佈常衞清香港上市百日戰報,截至目前,常衞清共銷售6000人/份,到檢逾2000人/份,常衞清的市場價格為3000港元/人份。雙方目前在香港的合作渠道超過50家,其中包括醫思健康、快驗保、港怡醫院、香港聖德肋撒醫院(St. Teresa's)、 香港體檢、尚至醫院等。諾輝健康與Prenetics今年5月23日達成深度戰略合作,推動“中國癌症早篩第一證”產品常衞清在中國香港上市,未來計劃覆蓋中國澳門、中國台灣,並同期探索“出海”東南亞。常衞清是Prenetics在以上區域獨家合作的結直腸癌早篩產品,今年6月份首發香港市場,並啟動全面户外及線上廣吿宣傳。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.